Similar articles

• Cholera toxin-mediated cellular immune responses against ovalbumin administered orally.

  Bowen JC, Reddy RM, Rouse BT. Bowen JC, et al. Adv Exp Med Biol. 1995;371B:1531-3. Adv Exp Med Biol. 1995. PMID: 7502851 No abstract available.
• Mucosal suppression by oral pre-treatment with ovalbumin and its conversion into stimulation when ovalbumin was conjugated to cholera toxin or its B subunit.

  van der Heijden PJ, Stok W, Bianchi AT. van der Heijden PJ, et al. Adv Exp Med Biol. 1995;371B:1251-5. Adv Exp Med Biol. 1995. PMID: 7502794 No abstract available.
• Modulating dendritic cells to optimize mucosal immunization protocols.

  Williamson E, Westrich GM, Viney JL. Williamson E, et al. J Immunol. 1999 Oct 1;163(7):3668-75. J Immunol. 1999. PMID: 10490961
• Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.

  Sun JB, Czerkinsky C, Holmgren J. Sun JB, et al. Scand J Immunol. 2010 Jan;71(1):1-11. doi: 10.1111/j.1365-3083.2009.02321.x. Scand J Immunol. 2010. PMID: 20017804 Review.
• Modulation of intestinal permeability: a novel and innovative approach for the oral delivery of drugs, macromolecules and antigens.

  Watts TL, Fasano A. Watts TL, et al. Biotechnol Genet Eng Rev. 2000;17:433-53. doi: 10.1080/02648725.2000.10648001. Biotechnol Genet Eng Rev. 2000. PMID: 11255677 Review. No abstract available.